Cargando…

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

Immediate-release (IR) formulation of linaclotide 290 μg improves abdominal pain and constipation (APC) in patients with irritable bowel syndrome (IBS) with constipation. Delayed-release (DR) formulations were developed on the premise that targeting the ileum (delayed-release formulation 1 [DR1]) or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chey, William D., Sayuk, Gregory S., Bartolini, Wilmin, Reasner, David S., Fox, Susan M., Bochenek, Wieslaw, Boinpally, Ramesh, Shea, Elizabeth, Tripp, Kenneth, Borgstein, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279899/ https://www.ncbi.nlm.nih.gov/pubmed/33065589 http://dx.doi.org/10.14309/ajg.0000000000000967

Ejemplares similares

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
por: Brenner, Darren M., et al.
Publicado: (2023)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults
por: Parker, Colleen H., et al.
Publicado: (2013)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study
por: Brenner, Darren M., et al.
Publicado: (2020)

Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide
por: Chandar, Apoorva Krishna
Publicado: (2017)

Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
por: Rey, Enrique, et al.
Publicado: (2017)

The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review
por: Baaleman, Desiree F., et al.
Publicado: (2021)

Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China
por: Liu, Lan, et al.
Publicado: (2022)

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
por: Eswaran, Shanti, et al.
Publicado: (2014)

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms
por: Serrano-Falcón, Blanca, et al.
Publicado: (2019)

Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study
por: Pohl, Daniel, et al.
Publicado: (2019)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation
por: Singh, Prashant, et al.
Publicado: (2022)

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study
por: Taylor, Douglas C.A., et al.
Publicado: (2019)

Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
por: Shah, Eric D, et al.
Publicado: (2018)

Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub‐cohort analysis of a phase III, randomized, double‐blind, placebo‐controlled trial
por: Peng, Li Hua, et al.
Publicado: (2022)

Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis
por: Shah, Eric D., et al.
Publicado: (2021)

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
por: Chang, L., et al.
Publicado: (2016)

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial
por: Lacy, Brian E., et al.
Publicado: (2015)

Functional constipation masked as irritable bowel syndrome
por: Tosto, Monica, et al.
Publicado: (2020)

Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
por: Dein, Eric J., et al.
Publicado: (2021)

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States
por: Nag, Arpita, et al.
Publicado: (2020)

Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
por: Patel, Sarah, et al.
Publicado: (2021)

The gut microbiome and irritable bowel syndrome
por: Menees, Stacy, et al.
Publicado: (2018)

Constipation-Predominant Irritable Bowel Syndrome Associated to Hyperprolactinemia
por: Seretis, C., et al.
Publicado: (2011)

Optimal management of constipation associated with irritable bowel syndrome
por: Furnari, Manuele, et al.
Publicado: (2015)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
por: Chey, William D., et al.
Publicado: (2020)

Lubiprostone for the Treatment of Adult Women with Irritable Bowel Syndrome with Constipation
por: Soubra, Mahmoud, et al.
Publicado: (2012)

Improving the Gastrointestinal Stability of Linaclotide
por: Braga Emidio, Nayara, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Different Doses of Linaclotide for Patients with Chronic Constipation: A Meta-Analysis and Bayesian Analysis
por: Yang, Jiao, et al.
Publicado: (2021)

White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome
por: Nan, Jiaofen, et al.
Publicado: (2018)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
por: Chey, William D., et al.
Publicado: (2021)

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
por: Shah, Eric D., et al.
Publicado: (2021)

Functional Constipation and Constipation-Predominant Irritable Bowel Syndrome in the General Population: Data from the GECCO Study
por: Enck, Paul, et al.
Publicado: (2016)

Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom
por: Layer, Peter, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_014s8m2h18g6ver0s1lgckc5gd